Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Significant Decrease in Short Interest

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) saw a large decrease in short interest in April. As of April 15th, there was short interest totaling 9,179 shares, a decrease of 28.7% from the March 31st total of 12,882 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average trading volume of 14,164 shares, the days-to-cover ratio is presently 0.6 days.

Pharming Group Stock Up 1.6%

NASDAQ PHAR traded up $0.26 during trading on Thursday, hitting $16.61. The company’s stock had a trading volume of 3,614 shares, compared to its average volume of 24,465. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.59 and a quick ratio of 2.03. The company has a market cap of $1.17 billion, a PE ratio of 1,660.50 and a beta of 0.05. The business’s 50 day simple moving average is $16.39 and its 200-day simple moving average is $16.52. Pharming Group has a fifty-two week low of $8.39 and a fifty-two week high of $21.34.

Pharming Group (NASDAQ:PHAR) last issued its quarterly earnings results on Thursday, March 12th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.08). The business had revenue of $106.50 million during the quarter, compared to analyst estimates of $111.76 million. Pharming Group had a return on equity of 1.08% and a net margin of 0.71%. On average, equities analysts anticipate that Pharming Group will post 0.38 EPS for the current fiscal year.

Institutional Investors Weigh In On Pharming Group

Large investors have recently bought and sold shares of the company. EverSource Wealth Advisors LLC purchased a new stake in Pharming Group in the second quarter valued at approximately $32,000. NewEdge Advisors LLC boosted its holdings in shares of Pharming Group by 11,310.3% in the 4th quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock valued at $510,000 after acquiring an additional 28,615 shares during the last quarter. Millennium Management LLC purchased a new stake in shares of Pharming Group in the 4th quarter valued at $360,000. Finally, SmartHarvest Portfolios LLC acquired a new stake in Pharming Group during the 4th quarter worth about $224,000. Hedge funds and other institutional investors own 0.03% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on PHAR. Zacks Research raised shares of Pharming Group from a “strong sell” rating to a “hold” rating in a report on Friday, April 10th. Weiss Ratings upgraded Pharming Group from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday. Oppenheimer restated an “outperform” rating and issued a $41.00 price target (down from $42.00) on shares of Pharming Group in a research note on Friday, March 13th. HC Wainwright reaffirmed a “buy” rating and issued a $37.00 target price on shares of Pharming Group in a report on Tuesday, March 24th. Finally, Canaccord Genuity Group began coverage on Pharming Group in a research note on Friday, April 10th. They set a “buy” rating and a $37.00 price target for the company. Three analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $38.33.

About Pharming Group

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.